Skip to main content
NCBI home page
Gut logoLink to Gut
. 1993;34(2 Suppl):S130–S132. doi: 10.1136/gut.34.2_suppl.s130

Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis.

N C Tassopoulos 1, M G Koutelou 1, G Papatheodoridis 1, H Polychronaki 1, I Delladetsima 1, T Giannikakis 1, A Todoulos 1, A Toliopoulos 1, A Hatzakis 1
PMCID: PMC1374038  PMID: 7686113

Abstract

To assess the safety and possible efficacy of recombinant human interferon alfa-2b in preventing the development of chronic hepatitis, 24 adults (eight men, 16 women) with acute non-A, non-B (NANB) hepatitis were recruited to a pilot study. Half of the cases were parenterally transmitted and half were community acquired. Twelve patients received 3 million units (MU) interferon three times weekly subcutaneously for six weeks and the remaining 12 patients received no treatment. Anti-hepatitis C virus (HCV) was detected in 14 (58.3%) of the 24 patients. The alanine aminotransferase activity returned to normal in nine of 12 interferon alfa-2b treated patients and six of 12 controls by week 52. Interferon alfa-2b was well tolerated, even in jaundiced patients, who only complained of mild flu like syndrome during the first week of treatment. These data are consistent with the hypothesis that interferon alfa-2b may help prevent progression to chronic hepatitis (interferon alfa-2b 25% v controls 50%), particularly in anti-HCV negative cases (interferon alfa-2b none of six v controls two of four). A randomised, double blind placebo-controlled trial is required, however, to substantiate these results further.

Full text

PDF
S130

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acute and chronic hepatitis revisited. Review by an international group. Lancet. 1977 Oct 29;2(8044):914–919. [PubMed] [Google Scholar]
  2. Berman M., Alter H. J., Ishak K. G., Purcell R. H., Jones E. A. The chronic sequelae of non-A, non-B hepatitis. Ann Intern Med. 1979 Jul;91(1):1–6. doi: 10.7326/0003-4819-91-1-1. [DOI] [PubMed] [Google Scholar]
  3. Davis G. L., Balart L. A., Schiff E. R., Lindsay K., Bodenheimer H. C., Jr, Perrillo R. P., Carey W., Jacobson I. M., Payne J., Dienstag J. L. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989 Nov 30;321(22):1501–1506. doi: 10.1056/NEJM198911303212203. [DOI] [PubMed] [Google Scholar]
  4. Di Bisceglie A. M., Martin P., Kassianides C., Lisker-Melman M., Murray L., Waggoner J., Goodman Z., Banks S. M., Hoofnagle J. H. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989 Nov 30;321(22):1506–1510. doi: 10.1056/NEJM198911303212204. [DOI] [PubMed] [Google Scholar]
  5. Nagata A., Kiyosawa K., Koike Y., Miura M., Gibo Y., Sodeyama T., Wada S., Akahane Y., Furuta S. Epidemiology of sporadic acute non-A, non-B hepatitis in Japan: a comparison with hepatitis A and B. Am J Gastroenterol. 1985 Apr;80(4):298–302. [PubMed] [Google Scholar]
  6. Omata M., Yokosuka O., Takano S., Kato N., Hosoda K., Imazeki F., Tada M., Ito Y., Ohto M. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet. 1991 Oct 12;338(8772):914–915. doi: 10.1016/0140-6736(91)91774-o. [DOI] [PubMed] [Google Scholar]
  7. Sampliner R. E., Woronow D. I., Alter M. J., Smallwood L. A., Tabor E., Deinhardt F., Roggendorf M., Gerety R. J. Community-acquired non-A, non-B hepatitis: clinical characteristics and chronicity. J Med Virol. 1984;13(2):125–130. doi: 10.1002/jmv.1890130203. [DOI] [PubMed] [Google Scholar]
  8. Tassopoulos N. C., Alikiotis M., Limotirakis F., Nicolakakis P., Mela H., Paralogou-Ioannides M. Acute sporadic non-A, non-B hepatitis in Greece. J Med Virol. 1988 Sep;26(1):71–77. doi: 10.1002/jmv.1890260110. [DOI] [PubMed] [Google Scholar]
  9. Tassopoulos N. C., Hatzakis A., Delladetsima I., Koutelou M. G., Todoulos A., Miriagou V. Role of hepatitis C virus in acute non-A, non-B hepatitis in Greece: a 5-year prospective study. Gastroenterology. 1992 Mar;102(3):969–972. doi: 10.1016/0016-5085(92)90184-z. [DOI] [PubMed] [Google Scholar]
  10. Van der Poel C. L., Cuypers H. T., Reesink H. W., Weiner A. J., Quan S., Di Nello R., Van Boven J. J., Winkel I., Mulder-Folkerts D., Exel-Oehlers P. J. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet. 1991 Feb 9;337(8737):317–319. doi: 10.1016/0140-6736(91)90942-i. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES